• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

水飞蓟宾通过调节 miR-122 的表达改善非酒精性脂肪性肝病:一项体内和体外研究。

Silibinin improves nonalcoholic fatty liver by regulating the expression of miR‑122: An and study.

机构信息

Endocrinology Department, Hebei General Hospital, Shijiazhuang, Hebei 050000, P.R. China.

出版信息

Mol Med Rep. 2021 May;23(5). doi: 10.3892/mmr.2021.11974. Epub 2021 Mar 24.

DOI:10.3892/mmr.2021.11974
PMID:33760189
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7974327/
Abstract

Silibinin is a flavonoid that improves fatty liver and insulin resistance. To elucidate the effect of silibinin on lipid deposition and the potential molecular mechanism, the present study conducted and experiments. In the experiments, mice were randomly divided into control, high‑fat and silibinin groups, while HepG2 cells were randomly divided into control, palmitic acid intervention and silibinin intervention groups. The mRNA, protein and miR‑122 expression associated with hepatic lipid metabolism were detected in each group. The results demonstrated that silibinin reduced the triglyceride content, miR‑122 expression and the mRNA and protein expressions of fatty acid synthase (FAS) and acetyl‑CoA carboxylase (ACC). Silibinin increased the mRNA and protein expression of carnitine palmitoyl transferase 1A (CPT1A). In the present study, HepG2 cells cultured with palmitate were treated with silibinin following overexpression of micro RNA (miR) 122. The results demonstrated that the mRNA and protein expression of FAS and ACC was increased, while that of CPT1A was decreased. Therefore, it could be deduced that silibinin improved lipid metabolism by reducing the expression of miR‑122 and inhibiting the expression of miR‑122 may be a new therapeutic target to improve fatty liver disease.

摘要

水飞蓟宾是一种改善脂肪肝和胰岛素抵抗的类黄酮。为了阐明水飞蓟宾对脂质沉积的影响及其潜在的分子机制,本研究进行了 和 实验。在 实验中,将小鼠随机分为对照组、高脂组和水飞蓟宾组,而 HepG2 细胞则随机分为对照组、软脂酸干预组和水飞蓟宾干预组。检测各组与肝脂代谢相关的 mRNA、蛋白和 miR-122 表达。结果表明,水飞蓟宾降低了甘油三酯含量、miR-122 表达以及脂肪酸合成酶(FAS)和乙酰辅酶 A 羧化酶(ACC)的 mRNA 和蛋白表达。水飞蓟宾增加了肉毒碱棕榈酰转移酶 1A(CPT1A)的 mRNA 和蛋白表达。在本研究中,用软脂酸培养的 HepG2 细胞在过表达 micro RNA(miR)122 后用水飞蓟宾处理。结果表明,FAS 和 ACC 的 mRNA 和蛋白表达增加,而 CPT1A 的表达减少。因此,可以推断出水飞蓟宾通过降低 miR-122 的表达来改善脂质代谢,抑制 miR-122 的表达可能是改善脂肪肝疾病的新治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d21a/7974327/a4ccdabf2c4f/mmr-23-05-11974-g08.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d21a/7974327/37029a91d03b/mmr-23-05-11974-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d21a/7974327/d5b7d9d8574d/mmr-23-05-11974-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d21a/7974327/8438bad992ff/mmr-23-05-11974-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d21a/7974327/ee8a0f0fdbda/mmr-23-05-11974-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d21a/7974327/c25a29d971d6/mmr-23-05-11974-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d21a/7974327/b80b1294bfa5/mmr-23-05-11974-g05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d21a/7974327/2a92f8b6661d/mmr-23-05-11974-g06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d21a/7974327/3835c6311414/mmr-23-05-11974-g07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d21a/7974327/a4ccdabf2c4f/mmr-23-05-11974-g08.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d21a/7974327/37029a91d03b/mmr-23-05-11974-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d21a/7974327/d5b7d9d8574d/mmr-23-05-11974-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d21a/7974327/8438bad992ff/mmr-23-05-11974-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d21a/7974327/ee8a0f0fdbda/mmr-23-05-11974-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d21a/7974327/c25a29d971d6/mmr-23-05-11974-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d21a/7974327/b80b1294bfa5/mmr-23-05-11974-g05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d21a/7974327/2a92f8b6661d/mmr-23-05-11974-g06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d21a/7974327/3835c6311414/mmr-23-05-11974-g07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d21a/7974327/a4ccdabf2c4f/mmr-23-05-11974-g08.jpg

相似文献

1
Silibinin improves nonalcoholic fatty liver by regulating the expression of miR‑122: An and study.水飞蓟宾通过调节 miR-122 的表达改善非酒精性脂肪性肝病:一项体内和体外研究。
Mol Med Rep. 2021 May;23(5). doi: 10.3892/mmr.2021.11974. Epub 2021 Mar 24.
2
Oxymatrine alleviated hepatic lipid metabolism via regulating miR-182 in non-alcoholic fatty liver disease.氧化苦参碱通过调节非酒精性脂肪肝病中的 miR-182 来缓解肝脂代谢。
Life Sci. 2020 Sep 15;257:118090. doi: 10.1016/j.lfs.2020.118090. Epub 2020 Jul 14.
3
Diosgenin ameliorates palmitic acid-induced lipid accumulation via AMPK/ACC/CPT-1A and SREBP-1c/FAS signaling pathways in LO2 cells.薯蓣皂苷元通过 AMPK/ACC/CPT-1A 和 SREBP-1c/FAS 信号通路改善棕榈酸诱导的 LO2 细胞脂质积累。
BMC Complement Altern Med. 2019 Sep 13;19(1):255. doi: 10.1186/s12906-019-2671-9.
4
Berberine Attenuates Development of the Hepatic Gluconeogenesis and Lipid Metabolism Disorder in Type 2 Diabetic Mice and in Palmitate-Incubated HepG2 Cells through Suppression of the HNF-4α miR122 Pathway.黄连素通过抑制肝细胞核因子4α/miR122途径减轻2型糖尿病小鼠和棕榈酸酯孵育的HepG2细胞中肝糖异生和脂质代谢紊乱的发展。
PLoS One. 2016 Mar 24;11(3):e0152097. doi: 10.1371/journal.pone.0152097. eCollection 2016.
5
Artemisia capillaris formula inhibits hepatic steatosis via an miR‑122‑induced decrease in fatty acid synthase expression in vivo and in vitro.茵陈蒿汤通过在体内和体外由miR-122诱导的脂肪酸合酶表达降低来抑制肝脂肪变性。
Mol Med Rep. 2016 Jun;13(6):4751-8. doi: 10.3892/mmr.2016.5131. Epub 2016 Apr 14.
6
Agonist of RORA Attenuates Nonalcoholic Fatty Liver Progression in Mice via Up-regulation of MicroRNA 122.激动剂 RORA 通过上调 microRNA-122 减轻小鼠非酒精性脂肪性肝病进展。
Gastroenterology. 2020 Sep;159(3):999-1014.e9. doi: 10.1053/j.gastro.2020.05.056. Epub 2020 May 22.
7
Alisol A 24-Acetate Prevents Hepatic Steatosis and Metabolic Disorders in HepG2 Cells.泽泻醇A 24-乙酸酯预防HepG2细胞中的肝脂肪变性和代谢紊乱。
Cell Physiol Biochem. 2016;40(3-4):453-464. doi: 10.1159/000452560. Epub 2016 Nov 25.
8
HNF-4α regulated miR-122 contributes to development of gluconeogenesis and lipid metabolism disorders in Type 2 diabetic mice and in palmitate-treated HepG2 cells.肝细胞核因子4α(HNF-4α)调控的miR-122促进2型糖尿病小鼠及棕榈酸处理的HepG2细胞中糖异生和脂质代谢紊乱的发生发展。
Eur J Pharmacol. 2016 Nov 15;791:254-263. doi: 10.1016/j.ejphar.2016.08.038. Epub 2016 Aug 31.
9
Effects of Water Extract on Alcoholic and Nonalcoholic Fatty Liver Impairment.水提取物对酒精性和非酒精性脂肪肝损伤的影响。
J Med Food. 2019 Dec;22(12):1262-1270. doi: 10.1089/jmf.2019.4493.
10
Effect of silibinin on CFLAR-JNK pathway in oleic acid-treated HepG2 cells.水飞蓟宾对油酸处理的 HepG2 细胞中 CFLAR-JNK 通路的影响。
Biomed Pharmacother. 2018 Dec;108:716-723. doi: 10.1016/j.biopha.2018.09.089. Epub 2018 Sep 21.

引用本文的文献

1
Silybin A from reprograms lipid metabolism to induce a cell fate-dependent class switch from triglycerides to phospholipids.来自水飞蓟宾A可重编程脂质代谢,以诱导细胞命运依赖性的类别转换,从甘油三酯转换为磷脂。
Theranostics. 2025 Jan 6;15(5):2006-2034. doi: 10.7150/thno.99562. eCollection 2025.
2
Inhibition of hepatic stellate cell activation by nutraceuticals: an emphasis on mechanisms of action.营养保健品对肝星状细胞激活的抑制作用:重点关注作用机制。
J Food Sci Technol. 2024 Nov;61(11):2046-2056. doi: 10.1007/s13197-024-06002-3. Epub 2024 May 18.
3
Herb-drug interactions of silybinin and cilofexor in beagle dogs based on pharmacokinetics by UPLC-MS/MS.

本文引用的文献

1
Apoptosis induction and proliferation inhibition by silibinin encapsulated in nanoparticles in MIA PaCa-2 cancer cells and deregulation of some miRNAs.纳米颗粒包裹的水飞蓟宾对MIA PaCa-2癌细胞的凋亡诱导和增殖抑制以及某些微小RNA的失调
Iran J Basic Med Sci. 2020 Apr;23(4):469-482. doi: 10.22038/ijbms.2020.39427.9349.
2
[Expert recommendations on standardized diagnosis and treatment for fatty liver disease in China (2019 revised edition)].《中国脂肪肝防治专家共识(2019年修订版)》
Zhonghua Gan Zang Bing Za Zhi. 2019 Oct 20;27(10):748-753. doi: 10.3760/cma.j.issn.1007-3418.2019.10.003.
3
Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases.
基于超高效液相色谱-串联质谱法的比格犬中水飞蓟宾与西洛菲索的药代动力学药物相互作用研究
Front Pharmacol. 2024 Feb 8;15:1334402. doi: 10.3389/fphar.2024.1334402. eCollection 2024.
4
In Vitro Influence of Specific Bacteroidales Strains on Gut and Liver Health Related to Metabolic Dysfunction-Associated Fatty Liver Disease.特定拟杆菌属菌株对与代谢功能障碍相关脂肪性肝病有关的肠道和肝脏健康的体外影响
Probiotics Antimicrob Proteins. 2025 Jun;17(3):1498-1512. doi: 10.1007/s12602-024-10219-1. Epub 2024 Feb 6.
5
Targeting dysregulated lipid metabolism in the tumor microenvironment.靶向肿瘤微环境中失调的脂质代谢。
Arch Pharm Res. 2023 Dec;46(11-12):855-881. doi: 10.1007/s12272-023-01473-y. Epub 2023 Dec 7.
6
Silibinin ameliorates deoxycholic acid-induced pyroptosis in steatotic HepG2 cells by inhibiting NLRP3 inflammasome activation.水飞蓟宾通过抑制NLRP3炎性小体激活减轻脱氧胆酸诱导的脂肪变性HepG2细胞焦亡。
Biochem Biophys Rep. 2023 Sep 13;35:101545. doi: 10.1016/j.bbrep.2023.101545. eCollection 2023 Sep.
7
Highly Accessible Computational Prediction and Experimental Validation: Novel Synthetic Phenyl Ketone Derivatives as Promising Agents against NAFLD via Modulating Oxidoreductase Activity.高可及性计算预测与实验验证:新型合成苯甲酮衍生物通过调节氧化还原酶活性成为治疗非酒精性脂肪性肝病的有前景的药物。
Oxid Med Cell Longev. 2023 Jan 9;2023:3782230. doi: 10.1155/2023/3782230. eCollection 2023.
8
Effect of LncPVT1/miR-20a-5p on Lipid Metabolism and Insulin Resistance in NAFLD.长链非编码RNA PVT1/微小RNA-20a-5p对非酒精性脂肪性肝病脂质代谢和胰岛素抵抗的影响
Diabetes Metab Syndr Obes. 2021 Nov 23;14:4599-4608. doi: 10.2147/DMSO.S338097. eCollection 2021.
非酒精性脂肪性肝病的流行病学、发病机制及治疗进展
Adv Sci (Weinh). 2018 Dec 12;6(4):1801585. doi: 10.1002/advs.201801585. eCollection 2019 Feb 20.
4
Dose translation between laboratory animals and human in preclinical and clinical phases of drug development.药物研发临床前和临床阶段实验动物与人体之间的剂量转换
Drug Dev Res. 2018 Dec;79(8):373-382. doi: 10.1002/ddr.21461. Epub 2018 Oct 21.
5
miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.非酒精性脂肪性肝病患者的 miRNA:系统评价和荟萃分析。
J Hepatol. 2018 Dec;69(6):1335-1348. doi: 10.1016/j.jhep.2018.08.008. Epub 2018 Aug 22.
6
The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View.非酒精性脂肪性肝病的自然史——不断变化的观点。
Clin Liver Dis. 2018 Feb;22(1):11-21. doi: 10.1016/j.cld.2017.08.003.
7
Treatment options for alcoholic and non-alcoholic fatty liver disease: A review.酒精性和非酒精性脂肪性肝病的治疗选择:综述。
World J Gastroenterol. 2017 Sep 28;23(36):6549-6570. doi: 10.3748/wjg.v23.i36.6549.
8
Silibinin Restores NAD⁺ Levels and Induces the SIRT1/AMPK Pathway in Non-Alcoholic Fatty Liver.水飞蓟宾可恢复 NAD⁺水平并诱导非酒精性脂肪肝中的 SIRT1/AMPK 通路。
Nutrients. 2017 Sep 30;9(10):1086. doi: 10.3390/nu9101086.
9
Metabolic Circuit Involving Free Fatty Acids, microRNA 122, and Triglyceride Synthesis in Liver and Muscle Tissues.游离脂肪酸、microRNA122 和甘油三酯合成在肝组织和肌肉组织中的代谢途径。
Gastroenterology. 2017 Nov;153(5):1404-1415. doi: 10.1053/j.gastro.2017.08.013. Epub 2017 Aug 9.
10
Silibinin Capsules improves high fat diet-induced nonalcoholic fatty liver disease in hamsters through modifying hepatic de novo lipogenesis and fatty acid oxidation.水飞蓟宾胶囊通过调节肝脏从头脂肪生成和脂肪酸氧化改善高脂饮食诱导的仓鼠非酒精性脂肪性肝病。
J Ethnopharmacol. 2017 Aug 17;208:24-35. doi: 10.1016/j.jep.2017.06.030. Epub 2017 Jun 23.